Phase III
Pfizer had a good day Wednesday with the announcement of positive results from two Phase III trials, one in moderate to severe atopic dermatitis and one in pneumococcal disease.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 19, 2020.
Researchers found fear of testing new treatments and possible side effects were common denominators among patients.
“We are pleased to see the sustained and meaningful survival benefit of Imfinzi for patients with small cell lung cancer after more than two years median follow up,” said Jose Baselga, Astra Zeneca’s executive vice president, Oncology R&D.
No more patients will be enrolled in the trials and current treatment “will cease” while they determine the risks and plans for the trials.
As the world waits with bated breath for a treatment for COVID-19, all eyes are on Gilead Science’s antiviral drug remdesivir as a potential candidate.
Inside the U.S., the first clinical trial for a vaccine to the novel coronavirus that causes COVID-19 began today.
The companies jointly announced that their Phase III JAVELIN Head and Neck 100 trial of Bavencio (avelumab) with chemoradiotherapy for untreated locally advanced squamous cell carcinoma of the head and neck was unlikely to hit the primary endpoint.
The primary endpoint was a statistically significant improvement in progression-free survival for the combination versus platinum-based chemotherapy.
MedDay Pharmaceuticals announced its MED1003 failed to meet its primary and secondary endpoints in the second pivotal Phase III trial for progressive multiple sclerosis.
PRESS RELEASES